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Introduction
β-Catenin plays a signiﬁ   cant role in the regulation of 
mammary development and tumorigenesis. At the plasma 
membrane, β-catenin aids cadherins in maintain  ing 
mammary epithelial integrity. In the nucleus, β-catenin 
regulates gene expression programs that are essential for 
mammary stem cell biology during mammary develop-
ment. Loss of β-catenin from cell–cell adhesive junctions 
or elevation in the cytosol and nucleus can occur 
independently by numerous routes. Importantly, both 
events predispose the breast to cancer. In the present 
article we review pathways relevant to breast that feed 
into the β-catenin signaling node, the role of β-catenin 
signaling in normal mammary development, and the 
eﬀ  ects of deregulating β-catenin on breast cancer.
Upstream regulators
Cadherin association
Breast epithelium is bilayered, comprising an inner 
luminal layer and a surrounding basal layer. In normal 
breast, the majority of β-catenin localizes to cell–cell 
adherens junctions through association with cadherins 
and only a minor portion is involved in signaling.
Th  e importance of the cadherin/catenin complex for 
epithelial integrity and survival has been demonstrated 
by conditional deletion of E-cadherin. E-cadherin null 
cells undergo apoptosis but in the absence of p53 these 
cells survive and recapitulate many features of lobular 
breast cancer [1-3]. In humans, lobular breast cancer is 
associated with irreversible E-cadherin loss and transient 
changes in cadherin expression facilitate metastasis in 
many ductal breast cancers [4].
Although the consequences of β-catenin deletion have 
not been experimentally investigated, loss of cadherin-
bound β-catenin correlates signiﬁ  cantly with poor out-
come in breast cancer [5]. Th  is loss can occur in three 
ways. Factors such as transforming growth factor beta 
(TGFβ), and some Wnts, reduce catenin localization to 
adherens junctions by increasing Snail, Slug, Twist, Siah 
interacting protein (SIP) and WISP3 expression (for a 
review see [6]), which suppress E-cadherin transcription. 
Similarly, loss of p120ctn – which prevents cadherin inter-
nalization – reduces membrane-bound β-catenin by de-
stabil  iz  ing E-cadherin [7]. Th   e major mechanism aﬀ  ect-
ing catenin localization to the plasma membrane, how-
ever, involves phosphorylation. Many tyrosine kinases, 
notably epidermal growth factor receptor/ErbB1/Her1, 
Met, Abl, Src and Fer, directly regulate cadherin/catenin 
aﬃ   nity for one another and are strongly implicated in 
breast cancer [8-14]. For instance, ErbB2/Her2/c-Neu 
mutation drives 30% of breast cancer, and increased β-
catenin-ErbB2/Her2/c-Neu association has been docu-
mented in human inﬁ  ltrating ductal adenocarcinoma and 
metastases [15,16]. Recent studies have also revealed that 
serine/threonine phosphorylation of the N-terminal 
domain of β-catenin by GSK3β and CK1 kinases plays a 
signiﬁ  cant role in compartmentalizing β-catenin [17]. A 
further mechanism of cadherin/catenin disruption involves 
the transmembrane mucin, MUC1, which competes with 
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© 2010 BioMed Central Ltdcadherins for catenin association [18,19]. MUC1 is 
overexpressed in 90% of breast carcinomas and parous 
MMTV-Muc1 mice develop mammary tumors [20].
Canonical Wnt signaling
While cadherin/catenin complexes are critical to mammary 
integrity, cytosolic and nuclear β-catenin serve a distinct 
role, transducing signals from multiple pathways into 
cell-context-speciﬁ   c gene expression patterns that are 
essential for mammary development. Th   is role has been 
studied most intensively within the context of canonical 
Wnt signaling.
Wnts are secreted morphogens that provide positional 
information to neighboring cells through canonical and 
noncanonical signaling routes (for recent reviews, see 
[21,22] – primary references and a detailed description of 
Wnt pathways can be accessed online: http://www.
stanford.edu/~rnusse/wntwindow.html). In brief, the 
canonical Wnt pathway operates by stabilizing cytosolic β-
catenin (Figure 1). In the absence of Wnt signals, a 
multiprotein destruction complex – including the tumor 
suppressor adenomatous polyposis coli (APC) and Axin – 
facilitates serine/threonine phosphorylation of the N-
terminal domain of β-catenin, which leads to its ubiqui-
tination and proteosomal destruction. Wnt ligands prevent 
this sequence of events by binding to Frizzled receptors 
and signaling through the associated low-density 
lipoprotein-related proteins, LRP5/6. LRP signal  ing via 
Disheveled and Axin inhibits the destruction complex and 
thus induces cytoplasmic accumulation of β-catenin. Th  is 
accumulation promotes β-catenin trans  loca  tion to the 
nucleus, where it associates with T-cell factor/Lef DNA 
binding proteins, displaces trans  crip  tional repressors, and 
recruits B-cell lymphoma-9/legless, pygo  pus homolog 2 
(Pygo2) and other factors to induce cell-context-speciﬁ  c 
gene expression. Canonical Wnt signal  ing is highly 
conserved and, importantly, regulates stem cell dynamics 
in many tissues, including the breast [23].
Other pathways regulating β-catenin signaling
Although canonical Wnt signaling is the most well-
known path to β-catenin stabilization, numerous other 
signaling pathways – many of which are aberrant in 
breast cancer – also regulate β-catenin stability and 
trans  criptional activity (Figure 2). For example, the prolyl 
isomerase Pin1 prevents association of β-catenin with 
APC, providing a major Wnt-independent stabilization 
mechanism [24]. Akt and ILK also stabilize β-catenin by 
inhibiting GSK3β activity. Importantly, the tumor 
suppressor phos  phatase and tensin homolog (PTEN) 
inhibits both path  ways [25,26]. Additionally, members of 
the p53–DNA damage pathway, Siah-1 (RING domain 
protein; trans  criptional target of p53) and Ebi (F box 
protein) interact with APC to form an alternative 
destruction complex that recognizes and destroys β-
catenin regardless of its phosphorylation status [27-29]. 
Th  e p53 homolog, ΔNp63, was shown to be a target of 
p53-dependent destruction. During cancer, loss of p53 
permits the aberrant interaction of ΔNp63 with protein 
phosphatase (PP2A), which inhibits GSK3β leading to β-
catenin stabilization [30]. Finally, critical kinases of the 
NF-κB signaling pathway (IκB kinase (IKK)α and IKKβ) 
diﬀ  erentially regulate β-catenin trans  crip  tion as well as 
activity [31]. IKKα phosphorylation increases stability 
and transcriptional activity of β-catenin, while phos-
phory  lation by IKKβ decreases both [31]. In certain cell 
contexts, Wnts stimulate alternative eﬀ  ectors  termed 
non  canonical pathways that can anta  go  nize the β-catenin 
pathway (Figure 1). A web of regula  tory pathways thus 
con  verges on cytosolic β-catenin and becomes trans  duced 
into a series of thresholds that exquisitely regulate the 
timely development and cyclical remodeling of the 
mammary gland. (See Table 1 for a summary of the pheno-
types of transgenic and knockout mice used to study Wnt 
signaling in mammary develop  ment and cancer.)
β-catenin signaling and mammary stem cells
In many epithelia, including breast, Wnt pathway activity 
is critical for stem cell self-renewal and multipotency 
[23]. β-Catenin signaling exerts powerful eﬀ  ects  on 
mammary stem cells and progenitor cells.  In mice, 
mammary stem cells reside among diﬀ  erentiated 
myoepithelial cells of the basal layer and alveolar 
progenitors are scattered among the diﬀ  erentiated cells 
of the luminal layer [32,33]. Recent studies have shown 
that Lrp5 is expressed in the basal epithelium and cells 
with high expression have a 200-fold greater ability to 
regenerate a mammary tree when transplanted into 
cleared mammary fatpads. Conversely, Lrp5–/– cells lack 
this capability and show senescence in culture, demon-
strating that canonical Wnt signaling is a critical for 
normal mammary stem cell maintenance [34]. Support  ing 
this concept, exogenous Wnt 3A protects mammary stem 
cells from senescence and the loss of multipotency 
associated with long-term culture. Furthermore, MECS 
derived from mice where Wnt signaling is mildly 
derepressed outcompete wild-type MECS in mammary 
reconstitution assays [23]. Th  e diverse roles of β-catenin 
signaling during mammary development, which we will 
now review, may thus be understood in a uniﬁ  ed way when 
viewed through the lens of the highly conserved role of 
canonical Wnt signaling in regulating stem cell dynamics.
Wnt/β-catenin signaling during embryonic mammary 
development
Wnt signaling is essential for speciﬁ  cation and morpho-
genesis of the mammary gland [35]. Canonical Wnt 
signaling reporters deﬁ  ne the mammary lines and later 
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functional importance of Wnt signaling is demonstrated 
by experiments showing that Dkk1 suppresses early 
canonical Wnt signaling, subsequent Wnt10b induction 
along the mammary line and all placodal development 
[36]. Targeting other positive acting elements of the Wnt 
pathway, such as Lrp6, Lrp5, Lef1 and Pygo2, also results 
in placodal impairments, ranging from loss to reduced 
size and degeneration, while stimulating β-catenin 
signaling produces the converse eﬀ   ect – acceleration, 
expansion and induction of placodes and placodal markers 
(Wnt10b and T-box transcription factor-3) [37-40]. 
Candidate activators of early β-catenin signaling include 
Wnt3, Wnt6 and Wnt10b, which are expressed diﬀ  usely 
throughout the ectoderm as well as a genetic hierarchy of 
factors, including ventral bone morphogenetic protein-4, 
dorsal T-box transcription factor-3, neuregulin-3 and 
somitic Fgf10, which function upstream to deﬁ  ne  the 
dorsal–ventral position of Wnt10b and Lef1 induction 
along the mammary line [35,41-48]. While these 
up  stream factors are body-site speciﬁ  c, Wnt/β-catenin 
signaling is required universally by all mammary 
placodes – and indeed by all ectodermal appendages [36]. 
Downstream targets remain obscure but probably 
include ectodysplasin-A, which promotes placodal cell 
fate along the mammary line when overexpressed [49].
Canonical Wnt signaling is also essential for mammary 
morphogenesis when placodes invaginate to form ﬂ  ask-
shaped buds. While recombinant Wnt3a accelerates this 
process, placodes from Lef1–/– mice remain elevated and 
degenerate [36,37,50]. Bud invagination is dependent 
upon mammary mesenchyme speciﬁ   cation, which is 
governed by parathyroid hormone-related peptide 
(PTHrP). Signiﬁ   cantly, mesenchymal expression of 
canonical Wnt reporters, Lef1 and several target genes is 
dependent on PTHrP [51-56]. Microarray studies have 
begun to identify downstream eﬀ  ectors, and β-catenin 
target genes appear to represent an important module of 
the PTHrP-induced mammary mesenchyme speciﬁ  cation 
process [57]. Ectodermal β-catenin signaling is also 
Figure 1. Canonical and noncanonical Wnt signaling pathways. In the absence of Wnt ligand (left panel), β-catenin is bound by a destruction 
complex within which Axin and adenomatous polyposis coli (APC) serve as scaff  olds. Bound β-catenin is phosphorylated by glycogen synthase 
kinase-3β (GSK3β) and casein kinase 1 (CK1), then ubiquitinated by beta-transducing repeat-containing protein (β-TrCP) and targeted for 
proteasomal destruction. Binding of Wnt ligand (right panel) inhibits the destruction complex, allowing β-catenin to accumulate in the cytoplasm 
and translocate to the nucleus, where it binds Lef/T-cell factor (TCF) transcription factors and activates target genes. In addition, Wnt5a can activate 
noncanonical signaling pathways in cell-context-specifi  c ways. DKK, Dickkopf; FRP, frizzled-related protein; Lgs, legless; LRP, low-density lipoprotein-
related protein; Pygo2, pygopus homolog 2; WIF, Wnt inhibitory factor.
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Page 3 of 14important within a population of cells at the sprout tip 
that express Pygo2, a nuclear partner of β-catenin. Sprout 
downgrowth and branching are impaired in both 
Pygo2–/– mice and Lrp6–/– mice [38,39].
β-catenin signaling during pubertal mammary 
development
Hormones temporally regulate postnatal development of 
the mammary gland, but their actions are relayed 
spatially by local paracrine factors. During puberty, 
estrogen, growth hormone and local IGF stimulate cell 
proliferation within terminal end buds to produce ductal 
extension. No direct connection has been established as 
yet between estrogen and canonical Wnt signaling. 
Several Wnts peak in expression during puberty, how-
ever, and Wnt5a and Wnt7b mRNAs are particularly 
enriched in terminal end buds and Wnt2 in the surround-
ing stroma [58-62]. Most reporters of canonical Wnt 
Figure 2. β-Catenin is at the hub of multiple signaling pathways. Many signaling pathways regulate the stability or binding interactions of 
β-catenin. In the Wnt pathway, glycogen synthase kinase-3β (GSK3β) and casein kinase 1 (CK1) phosphorylate the N-terminal degron sequence of 
β-catenin to facilitate its destruction. The phosphatidylinositol-3-kinase (PI3K) and phosphatase and tensin homolog (PTEN) pathways also impinge 
upon β-catenin phosphorylation by regulating GSK3β activity. In addition, p53 induces the degradation of β-catenin through protein interactions 
involving Seven in absentia homolog 1 (Siah1), Siah interacting protein (SIP) and EBV-induced G-protein coupled receptor (Ebi), resulting in 
ubiquitination and degradation of β-catenin. Pin1 binds to β-catenin phosphorylated on S246P to prevent its association with adenomatous 
polyposis coli (APC). In the NF-κB pathway, IκB kinase (IKK)α and IKKβ phosphorylate β-catenin throughout the protein to activate and inhibit 
transcription, respectively, although the N-terminus is essential for IKKα regulation. Some proteins, such as those within the transforming growth 
factor beta (TGFβ) pathway and Sox17, regulate β-catenin in the nucleus by modulating its interaction with transcriptional co-activators Tcf/Lef. 
Other proteins, like enhancer of zeste homolog 2 (EZH2), interact with β-catenin to promote its translocation into the nucleus. A number of tyrosine 
kinases phosphorylate (both membrane bound and cytosolic) β-catenin to prevent its binding to the cadherin complex at the cell membrane. Src, 
epidermal growth factor receptor (EGFR), and erythroblastic leukemia viral oncogene-2 (ErbB2) have been shown or implicated to phosphorylate 
β-catenin on Y654, while Abelson tyrosine kinase (Abl) phosphorylates Y489. β-TrCP, beta-transducing repeat-containing protein; DKK, Dickkopf; Lgs, 
legless; LRP, low-density lipoprotein-related protein; MAPK, mitogen-activated protein kinase; NLK, Nemo-like kinase; Pygo2, pygopus homolog 2; 
sFRP, secreted frizzled-related protein; WIF, Wnt inhibitory factor.
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Page 4 of 14Table 1. Mouse models used to study canonical Wnt signaling in mammary development and cancer
Mouse model  Structural modifi  cation  Mammary phenotype  References
MMTV-ΔN89-β-catenin  Stabilizing deletion of fi  rst 89 amino acids of β-catenin   Expansion K18+CD29hi 49flo [67,75]
  Luminal expression  Precocious alveologenesis 
   Adenocarcinoma 
MMTV-ΔN90-β-catenin  Stabilizing deletion of fi  rst 90 amino acids of β-catenin   Hyperplasia  [90]
 Luminal  expression  Adenocarcinoma 
Catnb+/lox(ex3);WAP-Cre  Stabilizing deletion of Exon 3 (codons 5 to 80) of   Squamous metaplasia  [93]
 β-catenin
Catnb+/lox(ex3);MMTV-Cre Luminal  expression   
MMTV-ΔN90-β-catenin x   Stabilizing deletion of β-catenin on a p53 heterozygous  Adenocarcinomas  [175]
p53+/–   background
 Luminal  expression  Metastases 
K5-ΔN57-β-catenin  Stabilizing deletion of fi  rst 57 amino acids of β-catenin   Precocious development during pregnancy  [38,74]
 Basal  expression  Hyperbranching 
    Multiparous mice develop invasive basal-type carcinoma 
MMTV-Wnt1  Wnt1 expression in luminal epithelia  Expansion of K14+, cd24+, cd29/49fhi basal stem cells   [33,67,84,85]
   Hyperbranching   
   Adenocarcinoma 
MMTV-Wnt10b  Expression of long isoform of Wnt10b in luminal epithelia  Precocious alveologenesis  [61]
   Hyperbranching 
   Adenocarcinoma 
MMTV-Lrp6  Expression of Lrp6 in luminal epithelia  Hyperplasia no tumors  [88]
ApcMin/+  Truncating mutation of APC at codon 850  Focal alveolar hyperplasias  [178]
    Mammary carcinomas (7 to 20% depending on strain 
   background) 
Apc+/1572  Truncating mutation of APC at codon 1572  Multifocal mammary adenocarcinomas (85.7%)  [95]
   Pulmonary  metastases 
K14-cre-Apc580/+  Truncating mutation of APC at codon 580   Mammary adenocarcinomas  [94]
 Basal  expression   
BLG-Cre; Apc580S/580S  Truncating mutation of APC at codon 580   Delayed ductal morphogenesis  [179]
  Luminal expression   Metaplasia 
MMTV-rtTA;TRE2-myc-  Doxycycline-inducible Axin in luminal epithelia   Loss of alveologenesis  [76]
tagged Axin-(IRES) GFP
WAP-β-engrailed  β-engrailed expressed luminally  Failure to maintain alveoli   [77]
MMTV-β-engrailed   Lactation  defect 
Lrp5–/–  Loss of Lrp5  Loss of placodes  [34,39]
    Mild ductal hypoplasia 
    Reduced regenerative capacity 
    Resistant to Wnt-induced tumorigenesis 
Lrp6–/–  Loss of Lrp6  Impaired sprouting, placode and fat pad development  [40]
    Decreased number of TEBs in heterozygotes 
Wnt4–/–  Loss of Wnt4  Delayed side-branching  [69]
Wnt5a–/–  Loss of Wnt5a  Accelerated ductal morphogenesis  [64]
K5-rtTA/tetO-DKK1  Ectopic expression of Dkk1  Loss of mammary line and all placodal development  [36]
K14-Cre/Pygo2 fl  ox  Loss of Pygo2 in mammary epithelium  Loss and small placodes  [38]
    Progressive loss of progenitor cell population 
Pin1–/–  Loss of Pin1  Severe decrease in ductal and alveolar development   [80]
   during  pregnancy
RANK–/–  Loss of RANK receptor  Loss of alveologenesis  [78,79]
    Failure to lactate 
    Impaired side-branching in transplanted null outgrowths  
Lef1–/–  Loss of Lef1  Impaired placodes  [37]
    Impaired bud morphogenesis  
Rspo–/–  Loss of Rspo1  Defective side branching  [73]
APC, adenomatous polyposis coli; DKK, Dickkopf; GFP, green fl  uorescence protein; LRP, low-density lipoprotein-related protein; MMTV, mouse mammary tumor virus; 
Pygo2, pygopus homolog 2; RANK, receptor activator of NF-κB; TEB, terminal end bud; WAP, whey acidic protein.
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expression is seen in basal cells and stroma surrounding 
the terminal end buds [23]. Conductin/Axin2 is an 
endogenous target gene that is faithfully expressed in 
response to canonical Wnt signaling and serves as a 
nega  tive feedback loop to downregulate the pathway [63]. 
Th  ese observations indicate that β-catenin signaling 
occurs at low levels. Genetically reducing canonical Wnt 
receptors produces mild eﬀ  ects:  Lrp5–/– mutants and 
Lrp6+/– mutants show fewer terminal end buds, Lrp5–/– 
mutants show delayed ductal extension, and Lrp6+/– 
mutants show reduced ductal branching. Compound 
Lrp6+/–;Lrp5–/– mutants show no ductal outgrowth, 
however, demon  strating a requirement for canonical Wnt 
pathway activity [34,39,40].
Current evidence suggests that noncanonical Wnt 
antagonism of canonical Wnt pathways is important. For 
example, loss of Wnt5a, which stimulates noncanonical 
signaling pathways during other polarized morphogenic 
events, increases cytoplasmic and nuclear β-catenin and 
accelerates ductal outgrowth [64]. Importantly, Wnt5a is 
an essential mediator of TGFβ, suggesting that low 
thresholds of β-catenin signaling are maintained during 
pubertal ductal morphogenesis through TGFβ and 
Wnt5a antagonism.
Links between progesterone and β-catenin signaling 
during ductal maturation
A signiﬁ  cant body of data shows that progesterone not 
only promotes Wnt expression but also induces compe-
tence to respond to β-catenin signaling within speciﬁ  c 
mammary progenitors. Progesterone receptor (PR) is 
expressed in most luminal cells in juveniles but becomes 
downregulated and interspersed with PR-negative cells in 
adults. Th  is patterning event requires PR and generates 
PR-negative progenitors that produce side branches and 
alveoli during pregnancy [65]. Expression of a stabilized 
form of β-catenin lacking N-terminal phosphorylation 
degron sequences (MMTV-ΔN89β-catenin) uniformly 
within the luminal epithelium induces signaling within 
this progenitor population, resulting in precocious 
develop  ment at regular intervals along ducts [66,67]. In 
the absence of PR, however, ΔN89β is only able to 
produce this eﬀ  ect at ductal tips [66,67]. Th  is  observation 
suggests that PR speciﬁ  es and spatially patterns alveolar 
progenitors by inducing a factor that is essential for β-
catenin’s nuclear entry or transcriptional activity and 
thus renders cells poised to receive a β-catenin signal 
[66,67]. Proges  terone also induces several paracrine 
factors – for example, Wnt4 and receptor activator of 
NF-κB ligand (RANKL) – in PR-positive luminal cells 
that signal to their neighbors [68-70]. A recent study has 
highlighted the importance of these paracrine eﬀ  ectors 
during estrus, showing that their expression correlated 
with β-catenin target gene expression in both luminal 
and basal cells and with increased stem cell activity [71].
Canonical Wnt signaling during pregnancy
Wnts and RANKL also function downstream of proges-
terone to stimulate side-branching and alveolar develop-
ment during pregnancy [68-70]. Wnt4, Wnt5b and Wnt6 
peak sequentially – and deletion of the earliest, Wnt4, 
delays side-branching, whereas ectopic Wnt4 expression 
promotes side-branching [58,69,72]. Th   e gene for Rspo1 
– which encodes an alternative (non-Wnt) ligand for 
Lrp6, and activates β-catenin signaling – is expressed 
during early pregnancy, and its deletion similarly aﬀ  ects 
side-branching [73]. Canonical Wnt signaling exerts 
dose-dependent eﬀ  ects on ductal branching: ConductinlacZ/+ 
mice show no phenotype but further pathway de-
repression in ConductinlacZ/lacZ mice results in mild 
hyperbranching and strong activation in K5-ΔN57β-
catenin or MMTV-Wnt1 mice produces dramatic hyper-
branching and gross ductal distortion [23,67,74,75]. 
Importantly, canonical Wnt signaling in ConductinLacZ/
LacZ mice and in MMTV-Wnt1;ConductinLacZ/+ mice is 
detected in basal cells [67,69]. Th   is observation suggests 
that Wnts expressed by luminal cells regulate ductal 
morphogenesis in a paracrine manner by inducing a 
canonical Wnt signaling response in basal cells [67,69].
In sharp contrast, a series of studies have shown that 
activation of β-signaling within speciﬁ  c  hormone 
receptor-negative luminal cell populations promotes and 
is required for alveologenesis. Expression of MMTV-
ΔN89β-catenin within luminal cells induces precocious 
alveologenesis in virgin mice [67,75]. β-Catenin signaling 
reporters are transiently expressed during normal 
alveologenesis, and inhibiting endogenous β-catenin 
signaling within luminal cells by expressing a negative 
regulator (Axin) or a dominant negative form of β-
catenin (β-engrailed) prevents alveologenesis and caused 
alveolar degeneration [36,50,76,77]. Together, these 
studies establish that luminal β-catenin signaling is 
essential for alveologenesis and survival.
Th  e upstream activator remains to be deﬁ  ned but is 
unlikely to involve Wnts since luminal cells express no 
obvious Wnt receptor and alveologenesis proceeds in the 
absence of Lrp5 [34]. Intriguingly, RANKL stabilizes β-
catenin in other contexts and, like β-catenin, speciﬁ  cally 
promotes the proliferation of PR-negative cells [78,79]. 
RANKL–/– mice and mice expressing Axin show similar 
impairment in alveologenesis [76,79]. Impor  tantly, Pin1, 
which pro  vides a Wnt-independent route to β-catenin 
stabilization, is critical for alveolar develop  ment during 
pregnancy [24,80]. Downstream targets of β-catenin 
signaling remain obscure. C-myc and cyclin D1 are 
reduced and increased in mice where the pathway is 
suppressed and is increased, respectively [67,75-77]. 
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response to MMTV-ΔN89β-catenin, MMTV-Wnt1 and 
RANKL, and instead drives early and later postpartum 
waves of cell division [79,81,82].
In summary, Wnts and RANKL promote stem cell 
ampliﬁ  cation [33,71] and branching [58,69,72] by para-
crine induction of β-catenin signaling in basal cells 
[34,39,40,67,71]. In contrast, β-catenin signaling in 
luminal progenitors is essential for alveologenesis and is 
probably induced by Wnt-independent mechanisms (for 
a model, see Figure 3) [67,76,77].
Deregulating β-catenin signaling in mammary 
stem and progenitor cells induces cancer
Just as regulation of stem cells is key to understanding 
the function of β-catenin signaling during embryonic and 
adult mammary development, its proto-oncogenic 
properties may be viewed as arising from unbridled stem 
and early progenitor expansion. More than 25 years ago, 
retroviral insertion resulting in Wnt1 activation was 
found to induce mammary tumors – and, subsequently, 
transgenic expression of Wnt1, Wnt3 and Wnt10b was 
shown to produce similar eﬀ  ects [61,83,84]. A series of 
studies have revealed that exposure of glands to excessive 
Wnt1 or activated ΔN89β-catenin leads to progressive 
accumulation of cells displaying stem and progenitor 
marker proﬁ  les and enhanced colony-forming ability and 
bipotency in vitro [67,85-88]. Reporter studies indicate 
that Wnt1 activates β-catenin signaling in a paracrine 
manner, increasing basally located multipotent stem cells 
at the expense of diﬀ  erentiated myoepithelial cells [67]. 
Th  e pivotal role of a canonical Wnt pathway versus a 
noncanonical Wnt pathway in this process has been 
demonstrated by the fact that Lrp5–/– mice are highly 
resistant to Wnt1 tumor development and show signi-
ﬁ  cantly delayed tumor onset [39,40]. Collectively, these 
studies indicate that paracrine signals from MMTV-
expressing luminal cells promote β-catenin signaling 
within a basal stem cell population and induce mixed 
lineage tumors. In keeping with this scenario, continuous 
Wnt1 expression is required for tumor maintenance [89].
Mice expressing activated β-catenin from the MMTV 
promoter also develop adenocarcinoma with 100% pene-
trance [75,90]. In this mouse model, however, reporter 
studies have shown that β-catenin signaling occurs within 
a distinct subset of luminal cells scattered along ducts with 
alveolar progenitor marker proﬁ   les and functional 
characteristics [67]. Th   ese studies show that deregulation 
of β-catenin signaling within luminal progenitor cells also 
produces tumors of mixed lineage [67,85-88]. Signi  ﬁ  cantly, 
in humans, basal-type hormone receptor-negative breast 
cancer is thought to arise from luminal progenitors. Target 
genes include matrix metalloprotein ases, cyclin D1 and c-
myc, which are upregulated in both MMTV-Wnt1 and 
MMTV-ΔN89β-catenin glands. Cyclin D1, however, is 
dispensable for tumor initiation [81,91]. In fact, MMTV-
ΔN89β-catenin mice lacking cyclin D1 present acceler-
ated tumor onset and higher tumor burden [91]. Lastly, 
canonical Wnt pathway activity has been implicated in 
mediating radiation resistance in mammary Sca1-posi-
tive progenitors by inducing Survivin expression [92].
Th  e response to β-catenin signaling is highly context 
dependent. K5-ΔN57β-catenin mice develop basal pre-
neo  plasia and invasive ductal carcinomas, while activa-
tion of β-catenin by MMTV-cre-targeted or whey acidic 
protein-cre-targeted exon 3 deletion shows squamous 
metaplasia [74,93]. Likewise, a mutant APC generated 
mammary adenocarcinomas when expressed in the basal 
layer but induced squamous metaplasia when expressed 
in diﬀ  er  en  tiating luminal cells [94]. APC mutants have 
also revealed tissue-speciﬁ  c dose responses. Th  e  APCMin/+ 
mutation, which results in high levels of β-catenin, 
predominantly causes intestinal polyposis, while APC 
mutants that generate intermediate levels of β-catenin 
Figure 3. Hypothetical model for paracrine activation of 
β-catenin signaling in the mammary gland. Progesterone 
receptor (PR) induces Wnts and receptor activator of NF-κB ligand 
(RANKL). These paracrine factors bind to their respective receptors 
low-density lipoprotein-related protein (LRP)5/6 and RANK in 
basal cells. β-catenin signaling in this cell type induces stem cell 
amplifi  cation and branching. Transforming growth factor beta (TGFβ) 
signaling within stromal cells restrains ductal morphogenesis by 
inducing Wnt5a. Wnt5a antagonizes canonical Wnt signaling, possibly 
via noncanonical Wnt pathways. β-Catenin signaling in luminal 
progenitors is essential for alveologenesis. As luminal cells lack Wnt 
receptors, however, it is likely that β-catenin signaling is induced in 
this cell-type by Wnt-independent mechanisms.
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background inﬂ   uences the tumorigenic properties of 
APCMin/+ and genetic studies have begun to identify 
tissue-speciﬁ  c modiﬁ  er loci [96].
Tumor microenvironmental factors also exert powerful 
eﬀ  ects on the tumor phenotype. For example, inhibiting 
TGFβ signaling in stromal cells by expression of a 
dominant negative receptor (metallothionine inducible 
dominant-negative TGFβ receptor II transgene) increases 
β-catenin signaling within the epithelium of MMTV-
Neu-induced and MMTV-PyVmT-induced tumors. Th  is 
is accompanied by a remarkable change in tumor 
phenotype from one that is principally luminal to one 
with mixed luminal and basal cell types [97]. Similar 
eﬀ  ects are produced by eliminating the TGFβ target gene 
and the paracrine eﬀ   ector, Wnt5a [97]. Th  e tumor 
microenvironment is in turn inﬂ  uenced by Wnt1, which 
impairs laminin deposition, disrupts cell polarity, 
promotes stromal hyperplasia and induces hedgehog 
signaling activity, suggesting important connections 
between these pathways in tumor onset [67,98].
β-catenin in human breast cancer
Studies in mice strongly suggest that deregulated β-
catenin signaling increases the breast cancer risk by 
inducing stem and early progenitor cell accumulation 
[67,85]. Consistent with this hypothesis, a gene expres-
sion signature derived from MMTV-Wnt1 tumor-
initiating cells was found to have prognostic value in 
determining poor outcome associated with speciﬁ  c 
breast cancer types, including basal-like and hormone 
receptor-negative cancers [99]. Genes of the canonical 
Wnt pathway featured prominently in a breast-to-lung 
metastasis signature that was signiﬁ  cantly  correlated 
with poor prognosis and reduced overall survival. Finally, 
Wnt1 tumors share transcriptional patterns with 
BRCA1+/– tumors and human basaloid tumors, and 
several studies have linked Lrp6 and nuclear β-catenin 
with triple-negative breast cancer [40,100-103].
Stabilizing mutations in the β-catenin N-terminal 
sequence found in other human cancers are uncommon 
in breast cancer and, until recently, were only reported in 
benign ﬁ   bromas [104,105]. Such mutations have now 
been found in 25% of metaplastic breast cancers [106]. In 
contrast to the rarity of mutation, β-catenin expression 
and/or localization are often abnormal in human breast 
cancer [5,24,106-109]. Increased cytoplasmic and nuclear 
β-catenin levels have been documented in 40% of 
primary breast cancers and correlated with poor prog-
nosis and worse patient survival [24,107,109-114]. Th  ese 
observations suggest that upstream elements of Wnt and/
or other pathways that stabilize β-catenin catenin are 
deregulated in breast cancer. Indeed, a signiﬁ  cant 
number of breast tumors develop in an environment of 
unopposed Wnt ligand activity [112,115-120]. Inactiva-
tion of genes encoding secreted Wnt pathway inhibitors, 
such as secreted frizzled-related protein (sFRP), Wnt 
inhibitory factor and DKK, occurs frequently in breast 
cancer. sFRP1 levels are diminished in inﬁ  ltrating  (or 
invasive) ductal carcinoma, and gain and loss of sFRP1 
suppresses and promotes invasive  ness of breast cancer, 
respectively [112,116,  117,  119,  120]. sFRP1, sFRP5, Wnt 
inhibitory factor-1 and DKK3 are transcrip  tionally 
silenced by promoter methy  lation in 27 to 100% of breast 
cancers [118,121-125]. Silencing of sFRP1, in particular, 
is a prognostic indicator of poor overall survival. One 
study found DKK1 to be preferentially expressed in 
hormone receptor-negative cancers; as DKK is a Wnt 
target gene, however, this elevation may actually indicate 
augmented pathway activity [126].
Th   ere is also mounting evidence for excess Wnt ligand 
production, aberrant receptor activation and loss of 
noncanonical Wnt antagonism in human breast cancer. 
Wnt2, Wnt4 and Wnt10b mRNA upregulation has been 
reported [112,127-134]. Wnt5a, which negatively 
regulates β-catenin activity during mammary develop-
ment, is lost in a proportion of human inﬁ  ltrating (or 
invasive) ductal carcinoma and is a powerful predictor of 
recurrence [135]. FRZ1 and FRZ2 upregulation occurs 
and a splicing mutation in LRP5 that induced β-catenin 
activity was found in 85% of tumors [136,137]. Two 
studies have reported increased LRP6 expression in 
human breast cancer, particularly in triple-negative 
basal-like subtypes [40,102]. One study showed that 
Mesd, an inhibitor of Lrp5/6 folding, suppressed growth 
of MMTV-Wnt1 tumors despite the presence of excess 
ligand and without adverse eﬀ  ects on normal Wnt-driven 
processes, suggesting that Lrp6 may have potential as a 
therapeutic target [102].
Disheveled, which promotes β-catenin signaling, is 
upregulated in up to 50% of primary breast cancers 
[113,138]. Moreover, although mutations in negative 
regu  la  tory components such as APC and Axin, are rare, 
loss of heterozygosity, downregulation or epigenetic 
silencing of these genes occurs in up to 70% of breast 
tumor cell lines and cancers [105,108,109,114,139-152]. 
Nuclear transcriptional cofactors such as Pygo2 show 
upregulated expression in a number of human invasive 
ductal cancers and are required for anchorage-inde  pen-
dent growth in human breast cancer cell lines [153]. 
EZH2, which promotes nuclear translocation of β-catenin 
and transcriptional activity, induces ductal hyper  plasia 
and involution defects in MMTV-EZH2 mice and is 
highly expressed in human breast carcinomas [154].
A number of Wnt target genes are implicated in breast 
cancer. Genes encoding c-myc and cyclin D1 are ampliﬁ  ed 
and upregulated in 40% of human breast cancers 
[107,155-158]. Cyclin D1 is dispensable for Wnt or 
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Wnt signaling by suppressing DKK and sFRP1, providing 
positive feedback to sustain the cancerous state [81,91, 
159]. Other relevant β-catenin targets include WISP1, 
Slug, Twist, Sox17, and Limb Heart Bud [100,160-163]. 
Sox17, a transcriptional antagonist of canonical Wnt 
signaling, is epigenetically silenced in 74.3% of breast 
tumors [162]. Limb Heart Bud, an important embryonic 
patterning gene, is upregulated in MMTV-Wnt tumors 
and many human breast cancers. Th  is gene is highly 
expressed in 50% of basal breast cancers, again suggesting 
that this breast cancer subtype may involve reactivation 
of dormant developmental signaling pathways [163].
An increasing body of evidence suggests that 
stabilization of β-catenin by Wnt-independent routes, 
such as Pin1, p53, PTEN/Akt and NF-κB pathways, plays 
a signiﬁ   cant role in breast cancer. For example, Pin1 
upregulation correlates with increasing cancer grade 
(25% in ductal carcinoma in situ, 71.4% in grade II 
tumors, and 89.5% in grade III tumors) [164], and is asso-
ciated with increased expression of β-catenin in breast 
tumors [24]. Components of the NF-κB pathway, which 
can diﬀ  erentially regulate β-catenin, are also activated in 
estrogen receptor-negative/ErbB2-positive breast cancers 
(86%) [165].
Loss of PTEN and p53 tumor suppressors has also been 
linked to induction of β-catenin in breast cancer. 
Germline PTEN mutations are common in patients with 
Cowden’s syndrome, showing a lifetime risk of 25 to 50% 
for developing breast cancer, and sporadic PTEN loss 
correlates with invasive breast carcinomas (48%, n = 151) 
[166,167]. Signiﬁ  cantly, overexpression of PTEN partially 
inhibits Wnt-induced tumorigenesis; conversely, loss of 
PTEN and activation of Akt caused an expansion of 
normal and malignant breast stem cells via activation of 
β-catenin [26,167,168]. Th   ese data suggest that the ability 
of PTEN to act as a tumor suppressor is mediated partly 
through the Wnt pathway. In addition to PTEN, inhibitor 
of diﬀ   erentiation binding-1, Slit-2 and melanoma 
diﬀ  erentiation association gene-7 proteins all regulate β-
catenin in breast cancer cells through the phosphatidyl-
inositol-3-kinase pathway [169-171].
Mutations in the p53 gene cause the heritable disease 
Li–Fraumeni syndrome, which is characterized by an 
18-fold enhancement in susceptibility to breast cancer. 
p53 mutation occurs in 50% of all human cancers and in 
20% of sporadic breast cancer (for a review see [172]). β-
Catenin is downregulated by p53 and is also degraded 
through a p53-dependent mechanism, which included 
Siah1, SIP and Ebi [27-29]. Adding to the complexity, 
Siah1 has splice variants that diﬀ  erentially  aﬀ  ect  β-
catenin in breast cancer cells [173,174]. MMTV-ΔNβ-
catenin tumors induced in p53+/– mice are more 
malignant and metastatic than those in p53+/+ mice [175]. 
Likewise, patients with breast cancers displaying high 
levels of β-catenin and p53 had worse survival [176]. 
Additionally, p63 was shown to be highly upregulated in 
metaplastic breast carcinomas (86.7%, n = 15) [177].
Conclusions
Evidence from murine models show that deregulated β-
catenin signaling in basal stem cells or luminal pro-
genitors induces breast tumors. Th  is event correlates 
with disturbances in the homeostatic balance between 
stem cell and early progenitor cell self-renewal and the 
production of diﬀ  erentiated progeny. Th   ere are numerous 
pathways, in addition to the canonical Wnt pathway, 
which regulate β-catenin. Mutations in β-catenin are rare 
but deregulated β-catenin signaling occurs frequently in 
human breast cancer and may be particularly relevant for 
basal-type and triple-negative subtypes, suggesting 
important links between reactivation of developmental 
pathways and this breast cancer subtype.
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